N
Nuvectis Pharma, Inc. (NVCT)
NCM – Real vaqt narxi. Valyuta: USD
7.48
-0.33 (-4.23%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.43
-0.05 (-0.63%)
Bozordan keyin: Mar 27, 2026, 5:48 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
7.48
-0.33 (-4.23%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
7.43
-0.05 (-0.63%)
Bozordan keyin: Mar 27, 2026, 5:48 PM EDT
Nuvectis Pharma, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, onkologiyada tibbiy ehtiyojlari qoplanmagan jiddiy kasalliklarni davolash uchun aniq dorilarni ishlab chiqishga qaratilgan. Kompaniya NXP900, kichik molekulali dori nomzodini ishlab chiqmoqda, bu esa qattiq o'smalarni davolash uchun proto-onkogen c-Src va YES1 kinazalarini ingibitsiya qiluvchi 1b-bosqich klinik sinovdan o'tmoqda. Kompaniya avval Centry Pharma, Inc. nomi bilan tanilgan va 2021-yil iyul oyida Nuvectis Pharma, Inc. nomini o'zgartirgan. Nuvectis Pharma, Inc. 2020-yilda ro'yxatga olingan va Nyu-Jersi shtatining Fort Li shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer |
| Mr. Michael Carson CPA | Vice President of Finance |
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-04 | 10-Q | tmb-20250930x10q.htm |
| 2025-09-25 | 8-K | tm2526892d1_8k.htm |
| 2025-08-05 | 8-K | tm2522415d1_8k.htm |
| 2025-06-13 | 8-K | tm2518009d1_8k.htm |
| 2025-05-09 | 8-K | tm2514418d1_8k.htm |
| 2025-05-06 | 10-Q | tmb-20250331x10q.htm |
| 2025-04-28 | DEF 14A | tm252541-4_def14a.htm |
| 2025-02-25 | 10-K | tmb-20241231x10k.htm |
| 2025-01-03 | S-8 | tm251759d1_s8.htm |
| 2024-11-05 | 10-Q | tmb-20240930x10q.htm |